Home › Ulcerative Colitis › South Carolina
Pag-aaral pangklinika para sa Ulcerative Colitis sa South Carolina
14 pag-aaral para sa Ulcerative Colitis ang naghahanap ng mga kalahok sa mga site sa South Carolina.
Mga Lungsod sa South Carolina
Opisyal na teksto ng pag-aaral (English)
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Medical University of South Carolina, Charleston
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07415044Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Associates - Patewood, Greenville
Nagre-recruitPhase 3
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06937086LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Gastroenterology Associates, P.A. of Greenville, Greenville
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07186101A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Palmetto Primary and Specialty Care Physicians, Charleston, Summerville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07577856A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Palmetto Primary Care Physician Division of Gastroenterology, Summerville
Nagre-recruitPhase 4
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT06581328Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Associates - Patewood /ID# 283870, Greenville
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT07697456A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
- Patewood Medical Campus /ID# 272477, Greenville
Nagre-recruitPhase 3
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT07071519An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- Medical University of South Carolina (MUSC), Charleston
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 64 · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT06398626An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Biocentric Health Research Partner, West Columbia
Nagre-recruitPhase 3
Edad 16 hanggang 80 · Lahat ng kasarian · Na-update Okt 23, 2026 · NCT07184996A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Local Institution - 0099, Charleston
Nagre-recruitPhase 2/3
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Okt 20, 2026 · NCT05076175A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Medical University of South Carolina, Charleston
Nagre-recruitPhase 3
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Okt 9, 2026 · NCT06405087BOOM-IBD2 Pivotal Clinical Trial
- Columbia Digestive Health Research (Objective Health), Columbia
Nagre-recruit
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06571669A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Medical University of South Carolina, North Charleston
Nagre-recruitPhase 3
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06100289A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Greenville
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Mar 12, 2026 · NCT07113522Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.